Patent intelligence · US
US 12188926
Stimuli responsive microsphere composites
Stimuli responsive microsphere composites
Patent details — US 12188926
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 7, 2025
- Expiration
- Jan 2, 2045
- Applicant
- SOUTH DAKOTA BOARD OF REGENTS
- Claims
- 7
- CPC classes
- A61K, A61K9/0009, A61K9/5084
Quick answer
US 12188926 (Stimuli responsive microsphere composites) is held by SOUTH DAKOTA BOARD OF REGENTS. Status: granted. Granted Jan 7, 2025. Expires Jan 2, 2045 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SOUTH DAKOTA BOARD OF REGENTS
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K9/0009, A61K9/5084
More from SOUTH DAKOTA BOARD OF REGENTS
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 12188926?
US 12188926 (Stimuli responsive microsphere composites) is held by SOUTH DAKOTA BOARD OF REGENTS. Status: granted. Granted Jan 7, 2025. Expires Jan 2, 2045 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12188926?
SOUTH DAKOTA BOARD OF REGENTS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 12188926 expire?
Our index shows an expiration date of Jan 2, 2045 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.